11/19
08:20 am
crdf
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]
Low
Report
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]
11/19
08:00 am
crdf
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Low
Report
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
11/19
03:05 am
crdf
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development [Yahoo! Finance]
Low
Report
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development [Yahoo! Finance]
11/9
08:42 am
crdf
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/8
02:32 pm
crdf
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
11/7
04:18 pm
crdf
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
High
Report
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
11/7
04:05 pm
crdf
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
High
Report
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
10/30
04:30 pm
crdf
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Low
Report
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
10/4
01:13 pm
crdf
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market [Seeking Alpha]
Low
Report
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market [Seeking Alpha]
10/1
05:46 pm
crdf
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight [Yahoo! Finance]
9/6
08:07 am
crdf
Cardiff Oncology, Inc. (NASDAQ: CRDF) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.
Medium
Report
Cardiff Oncology, Inc. (NASDAQ: CRDF) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.